Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.

Galimberti, Sara; Cervetti, Giulia; Guerrini, Francesca; Testi, Rossana; Pacini, Simone; Fazzi, Rita; Simi, Paolo; Petrini, Mario

Galimberti, Sara; Cervetti, Giulia; Guerrini, Francesca; Testi, Rossana; Pacini, Simone; Fazzi, Rita; Simi, Paolo; Petrini, Mario.

Affiliation

Galimberti S; Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, Ospedale S. Chiara, Pisa, Italy. s.galimberti@med.unipi.it

Cancer Genet Cytogenet ; 162(1): 57-62, 2005 Oct 01.

Article in En | MEDLINE | ID: mdl-16157201

Subject(s)

Fusion Proteins, bcr-abl/metabolism; Genes, MDR; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Piperazines/therapeutic use; Pyrimidines/therapeutic use; Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Genes, MDR Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Genet Cytogenet Year: 2005 Type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links